Change and significance of serum sICAM-1 and sVCAM-1 levels in acute myeloid leukemia

Objective:To study the change and significance of sICAM-1 and sVCAM-1 in patients with acute myelocytic leukemia(AML).Methods:Fifty-six AML patients were as trial group and 20 subjects were as control group;serum samples were obtained from patients in trial group before and after treatment and subjects in control group;concentrations of sICAM-1 and sVCAM-1 were determined with enzyme linked immunosorbent assay(ELISA) respectively.Results:Serum levels of sICAM-1 and sVCAM-1 in trial group were high before treatment,compared with control group,there was significant difference(P0.01);and were in normal levels in remissive patients after treatment,compared with control group,there was no significant difference(P0.05).Serum levels of sICAM-1 and sVCAM-1 in relapsed AML patients were elevated,compared with control group and remissive patients,there was significant difference(P0.01).Serum levels of sVCAM-1 in M4 and M5 were higher than those in other subtypes of AML(P 0.05).Patients with elevated serum levels of sICAM-1 and sVCAM-1 in initial had poorer response to treatment than those with normal serum levels of sICAM-1 and sVCAM-1. Conclusion:The change of sICAM-1 and sVCAM-1 of AML patients can used for the analysis of therapeutic effect,progress of disease and prognosis;and it can also provide useful information for the chemotherapy.